Immunotherapy-Chemo combo takes on advanced sarcoma

NCT ID NCT04577014

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding an experimental immunotherapy drug called retifanlimab to standard chemotherapy (gemcitabine and docetaxel) is safe and effective for people with advanced soft tissue sarcoma that cannot be removed by surgery. About 98 participants will receive the combination. The main goal is to see how many patients are still alive without their cancer getting worse after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: retifanlimab (immunotherapy) plus gemcitabine and docetaxel (chemotherapy)
What this could lead to: If it works, this combination could offer a new treatment option that helps control advanced soft tissue sarcoma for longer than chemotherapy alone.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants. The immunotherapy may not improve outcomes and could cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA SARCOMA,SOFT TISSUE SOFT TISSUE SARCOMA SOFT TISSUE SARCOMA ADULT

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.